| name | icsm-defer-tt-elevated-psa-or-nodules |
| description | Recommends postponing testosterone initiation and pursuing MRI or biopsy when PSA is elevated or a prostate nodule is detected on digital rectal examination; if evaluation shows no cancer, testosterone therapy may be considered. Triggered by clinician findings of elevated PSA (>4 ng/mL) or a palpable prostate nodule during DRE, prompting the question of whether to hold testosterone until prostate cancer is ruled out. |
Defer testosterone therapy until prostate evaluation if PSA elevated or nodules present
STEP 1 — Gather Information
Collect symptoms of hypogonadism, obtain morning total testosterone, perform digital rectal examination (DRE), and measure serum PSA.
→ Proceed to evaluate PSA and DRE findings.
STEP 2 — Rule In / Rule Out
Is PSA >4 ng/mL (or age‑adjusted threshold) or is a prostate nodule palpable on DRE?
- If yes → proceed to Step 3.
- If no → testosterone therapy may be considered after confirming hypogonadism.
→ Decision based on PSA/DRE results.
STEP 3 — Classify or Stratify
If PSA elevated or nodule present, obtain prostate MRI and/or targeted biopsy to rule out malignancy.
→ Proceed to prostate imaging/biopsy.
STEP 4 — Decide
If evaluation shows no cancer, testosterone therapy may be initiated; if cancer is diagnosed, refer to oncology and defer testosterone.
→ Initiate testosterone only after negative prostate evaluation; otherwise refer for cancer management.
Clinical Guardrails / Mimics / Pitfalls
Do not start testosterone in men with elevated PSA or nodule without urologic assessment; do not rely on PSA alone without DRE; do not ignore nodules; consider that PSA can be elevated by BPH, infection, or recent ejaculation; ensure biopsy is performed if MRI suspicious; avoid testosterone in known prostate cancer.
Concrete Clinical Example
A 58‑year‑old man presents with low libido and morning total testosterone 8 nmol/L. DRE reveals a firm nodule and PSA is 5.2 ng/mL. Testosterone is deferred; prostate MRI shows a suspicious lesion, biopsy confirms benign prostatic hyperplasia. After negative evaluation, testosterone therapy is started.
Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), Mohit Khera et al., 2025, DOI: 10.1093/sxmrev/qeaf036
